- Home
- LPTX vs DIBS Comparison
LPTX vs DIBS Comparison
Compare LPTX & DIBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- DIBS
- Stock Information
- Founded
- LPTX 2011
- DIBS 2000
- Country
- LPTX United States
- DIBS United States
- Employees
- LPTX N/A
- DIBS N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- DIBS Catalog/Specialty Distribution
- Sector
- LPTX Health Care
- DIBS Consumer Discretionary
- Exchange
- LPTX Nasdaq
- DIBS Nasdaq
- Market Cap
- LPTX 119.6M
- DIBS 130.0M
- IPO Year
- LPTX N/A
- DIBS 2021
- Fundamental
- Price
- LPTX $2.55
- DIBS $3.63
- Analyst Decision
- LPTX Strong Buy
- DIBS Buy
- Analyst Count
- LPTX 3
- DIBS 2
- Target Price
- LPTX $7.50
- DIBS $8.00
- AVG Volume (30 Days)
- LPTX 335.2K
- DIBS 100.2K
- Earning Date
- LPTX 11-13-2024
- DIBS 02-26-2025
- Dividend Yield
- LPTX N/A
- DIBS N/A
- EPS Growth
- LPTX N/A
- DIBS N/A
- EPS
- LPTX N/A
- DIBS N/A
- Revenue
- LPTX N/A
- DIBS $86,409,000.00
- Revenue This Year
- LPTX N/A
- DIBS $5.17
- Revenue Next Year
- LPTX N/A
- DIBS $7.90
- P/E Ratio
- LPTX N/A
- DIBS N/A
- Revenue Growth
- LPTX N/A
- DIBS N/A
- 52 Week Low
- LPTX $1.68
- DIBS $3.37
- 52 Week High
- LPTX $4.79
- DIBS $6.30
- Technical
- Relative Strength Index (RSI)
- LPTX 37.35
- DIBS 47.99
- Support Level
- LPTX $2.88
- DIBS $3.40
- Resistance Level
- LPTX $3.27
- DIBS $3.70
- Average True Range (ATR)
- LPTX 0.28
- DIBS 0.12
- MACD
- LPTX -0.06
- DIBS 0.02
- Stochastic Oscillator
- LPTX 12.71
- DIBS 60.81
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company's single reportable and operating segment contains two reporting units; 1stDibs, which consists of the company's online marketplace that enables commerce between sellers and buyers; and Design Manager, which is the company's separate online platform that is used to sell a software solution to interior designers. It generates revenue primarily from fees from seller marketplace services as well as other services, including advertisements and software services.